PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 3, 2026Alzheimer s & Dementia Translational Research & Clinical Interventions0 citationsOpen Access

Exclusions affect representativeness of Alzheimer's disease trial participants

View Full Paper
MAM T AshfordSan Francisco VA Medical CenterRTRachana TankUniversity of California, San FranciscoMKMohammed U. KabetoUniversity of Michigan

Key Points

  • Ineligibility affects 74.2% of potential participants, raising concerns about generalizability.
  • The most common reason for exclusion was cardiovascular conditions, impacting participant diversity.
  • Analysis of 2742 participants reveals links between ineligibility and factors like age and body mass index.
  • These findings highlight the need for broader inclusion criteria to improve representativeness in trials.

Abstract

A total of 2742 participants (74.2%) were deemed ineligible for the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial based on the medical exclusion criteria.The most common medical exclusion in this sample was for cardiovascular conditions.Ineligibility was associated with age, education, net worth, and body mass index.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ashford et al. (2026) studied this question.

synapsesocial.com/papers/69a75bdcc6e9836116a23f26https://doi.org/10.1002/trc2.70191
Ask AI
Helpful
Bookmark
Share
View Full Paper